Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Upper endoscopy is uncomfortable for most patients. Meperidine has both sedative and analgesic effects, so its use may be helpful for patients receiving upper endoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.

NCT01948921

Patients Undergoing Diagnostic EGD

COMPLETED NA

Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy

NCT01887184

Gastrointestinal Disease

COMPLETED PHASE3

Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD)

NCT01990937

Conscious Sedation Failure During Procedure

UNKNOWN PHASE4

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

NCT00937924

Endoscopic Ultrasound (EUS) Endoscopic Retrograde Cholangiopancreatography (ERCP)

COMPLETED PHASE4

Intranasal Dexmedetomidine Versus Intranasal Midazolam as a Premedication in Pediatrics Undergoing Upper GI Endoscopy

NCT06181682

Anesthesia

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Unsedated esophagogastroduodenoscopy (EGD) is a useful tool for upper gastrointestinal tract examination and therapy, but it is uncomfortable for many patients. Meperidine has been widely used in colonoscopic examination for many years; however, its use in EGD has not been completely evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophagogastroduodenoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

meperidine

25 mg of meperidine is injected intramuscularly before EGD

Group Type EXPERIMENTAL

Meperidine

Intervention Type DRUG

intramuscular, 25 mg, 5 to 10 minutes before EGD

placebo

placebo was given intramuscularly before EGD

Group Type PLACEBO_COMPARATOR

normal saline

Intervention Type DRUG

25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meperidine

intramuscular, 25 mg, 5 to 10 minutes before EGD

Intervention Type DRUG

normal saline

25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing diagnostic upper endoscopy in our endoscopic room were enrolled.

Exclusion Criteria

* A therapeutic upper endoscopic procedure, sedated endoscopy, contraindication to Buscopan (hyoscine N-butylbromide)
* Allergy to meperidine
* American Society of Anesthesiology (ASA) risk Class 3 or higher
* Renal failure
* Decompensated cirrhosis
* Aged less than 20 years or more than 65 years
* Pregnancy
* Refusal to provide written informed consent.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

Accepts Healthy Volunteers

No